Viking Therapeutics
176 posts
Viking Therapeutics
@Viking_VKTX
Novel therapeutics for metabolic
and endocrine disorders
Viking Therapeutics to ring the opening bell at the Nasdaq stock market on Monday, July 15. CEO Brian Lian to ring bell at Nasdaq MarketSite in Times Square, New York City.- Thanks to @Nasdaq for inviting Viking Therapeutics ($VKTX) to ring the opening bell on Monday, July 15. We had a great time and appreciate the visibility for our work developing novel therapies for metabolic and endocrine disorders, including #NASH youtu.be/wm53unyXFxw
- Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
- Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting® 2018 bit.ly/2FvCSrp
- Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
- Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
- Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting® 2018
- Viking Therapeutics to Present at Biotech Showcase 2019 bit.ly/2RtQtnD
- Viking Therapeutics to Participate in Upcoming Investor Conferences and Events
- Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease bit.ly/2Hnv32h
- Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
- Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA) bit.ly/2PmqoCM
